Abstract: Compounds are provided that comprise a ligand having a 5-substituted 2-phenylquinoline. In particular, the 2-phenylquinoline may be substituted with a cycloalkyl containing group at the 5-position. These compounds may be used in organic light emitting devices, in particular as red emitters in the emissive layer of such devices, to provide devices having improved properties.

Abstract: A compound including a ligand LA of Formula I is disclosed.

Abstract: Provided are organometallic compounds having a ligand LA of Formula I: Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: A compound comprising a heteroleptic iridium complex having a structure of Formula II, is provided. In Formula II, each of R1, R2, R3, R4, R5, and R6, is independently selected from the group consisting of hydrogen, deuterium, cycloalkyl, deuterated cycloalkyl, alkyl, and deuterated alkyl; at least one of R1, R2, R3, R4, R5, and R6 is not hydrogen or deuterium; and each R and R? is independently selected from a variety of substitutions. OLEDs and formulations containing the compound of Formula II are also provided.

Abstract: A compound comprising a first bidentate ligand LA, wherein LA comprises a structure of Formula I; wherein Z is selected from the group consisting of O, S, NR, BR, CRKRL, C?CRKRL, SiRKRL, —CRKRLCRMRN—, —SiRKRLSiRMRN—, —CRKRLO—, —SiRKRLO—, and —CRK?CRL—; wherein ring A, ring B, and ring C are each independently a 5-membered carbocyclic ring, 5-membered heterocyclic ring, 6-membered carbocyclic ring or 6-membered heterocyclic ring; wherein LA is coordinated to a metal M forming a 5-membered chelate ring; wherein M is selected from the group consisting of Ir, Pt, Pd, Ru, Rh, Os, Re, Cu, Ag, and Au; wherein RA, RB, and RC each represent mono to the maximum allowable substitution, or no substitution; wherein each R, RK, RL, RM, RN, RA, RB, and RC is independently a hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, germyl, boryl, selenyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, a

Abstract: Heteroleptic iridium complexes having the formula are disclosed. In this formula, R1, R2, R3, R4, R5, and R6, are selected from hydrogen, deuterium, cycloalkyl, deuterated cycloalkyl, alkyl, and deuterated alkyl, and can optionally be linked together to form a ring; at least one of R1, R2, R3, R4, R5, and R6 is cycloalkyl, deuterated cycloalkyl, alkyl, or deuterated alkyl; ring A is attached to the 4- or 5-position of ring B; and R and R? can represent any of a variety of subsitutents. These iridium compounds contain alkyl substituted phenylpyridine ligands, which provide these compounds with beneficial properties when the iridium complexes are incorporated into OLED devices.

Abstract: A compound containing indolocarbazole having a formula: Formula I is disclosed.

Abstract: A compound containing indolocarbazole having a formula: Formula I is disclosed.

Abstract: The present invention includes a new series of benzofused heterocyclic ligands for metal complexes. These complexes show promising photophysical performance when incorporated into OLEDs.

Abstract: A compound having the formula Ir(LA)n(LB)3?n is disclosed wherein LA is an aza-DBF ligand and LB is an alkyl-substituted phenylpyridine ligand, wherein the compound has a structure according to Formula I: wherein A1, A2, A3, A4, A5, A6, A7, and A8 comprise carbon or nitrogen; wherein at least one of A1, A2, A3, A4, A5, A6, A7, and A8 is nitrogen; wherein ring B is bonded to ring A through a C—C bond; wherein the iridium is bonded to ring A through a Ir—C bond; wherein X is O, S, or Se; wherein R1 and R2 each independently represent mono-, di-, tri-, tetra-substitution, or no substitution; wherein R? and R? each independently represent mono-, di-substitution, or no substitution; wherein any adjacent substitutions in R?, R?, R1, R2, R3, R4, R5, and R6 are optionally linked together to form a ring; wherein R1, R2, R?, and R? are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,

Abstract: Novel heteroleptic iridium carbene complexes are provided. The complexes have lower-than expected sublimation temperatures, which is beneficial for the processing of these materials in solid state applications. Selective substitution of the ligands provides for phosphorescent compounds that are suitable for use in a variety of OLED devices. The carbene complexes can also be used as materials in a hole blocking layer and/or an electron transport layer to improve device performance.

Abstract: A compound having a Pt tetradentate structure of Formula 1, is provided. In the structure of Formula 1, rings C and D each independently represent 5- or 6-membered carbocyclic or heterocyclic ring; L1, L2, and L3 are each independently a direct bond, BR, NR, PR, O, S, Se, C?O, S?O, SO2, SiRR?, GeRR?, alkyl, cycloalkyl, or a combination thereof; the sum of n1 and n2 is 1 or 2; X is selected from NRE, O, S, and Se; X3 and X4 each independently carbon or nitrogen; and one of Q1, Q3, and Q4 is oxygen, and the remaining two of Q1, Q3, and Q4 each represents a direct bond. Formulations and devices, such as an OLEDs, that include the compound of Formula 1 are also described.

Abstract: A compound useful as a host material in an OLED is provided. The compound includes at least one chemical group selected from the group consisting of triphenylene, carbazole, indolocarbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, aza-triphenylene, azacarbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene; wherein the compound is substituted by at least one R selected from the group consisting of alkyl, cycloalkyl, spiroalkyl, partially or fully deuterated variants thereof, partially or fully fluorinated variants thereof, and combination thereof.

Abstract: A compound of: is disclosed. In Formula IV, ring B and ring C are each independently a 5 or 6-membered carbocyclic or heterocyclic ring; A-B represents a bonded pair of carbocyclic or heterocyclic rings coordinated to a metal M via a nitrogen atom in ring A and an sp2 hybridized atom in ring B; A-C represents a bonded pair of carbocyclic or heterocyclic rings; M is a metal having an atomic number greater than 40; L? is a monoanionic bidentate ligand; m is the oxidation state of the metal M; and n is at least 1.

Abstract: A compound useful as a host material in an OLED is provided. The compound includes at least one chemical group selected from the group consisting of triphenylene, carbazole, indolocarbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, aza-triphenylene, azacarbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene; wherein the compound is substituted by at least one R selected from the group consisting of alkyl, cycloalkyl, spiroalkyl, partially or fully deuterated variants thereof, partially or fully fluorinated variants thereof, and combination thereof.

Abstract: An OLED containing an emissive dopant that is a heteroleptic complex having the formula Ir(LA-B)2(LC-D) is disclosed.

Abstract: A compound having a Pt tetradentate structure of Formula 1, is provided. In the structure of Formula 1, rings C and D each independently represent 5- or 6-membered carbocyclic or heterocyclic ring; L1, L2, and L3 are each independently a direct bond, BR, NR, PR, O, S, Se, C?O, S?O, SO2, SiRR?, GeRR?, alkyl, cycloalkyl, or a combination thereof; the sum of n1 and n2 is 1 or 2; X is selected from NRE, O, S, and Se; X3 and X4 each independently carbon or nitrogen; and one of Q1, Q3, and Q4 is oxygen, and the remaining two of Q1, Q3, and Q4 each represents a direct bond. Formulations and devices, such as an OLEDs, that include the compound of Formula 1 are also described.

Abstract: Provided are organometallic compounds. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: Novel organic materials containing indolocarbazoles as donor connected with electron acceptors such as quinoxaline or dibenzoquinoxaline for PHOLED devices are disclosed.

Abstract: A compound comprising a first bidentate ligand LA, wherein LA comprises a structure of Formula I; wherein Z is selected from the group consisting of O, S, NR, BR, CRKRL, SiRKRL, —CRKRLCRMRN—, —SiRKRLSiRMRN—, —CRKRLO—, —SiRKRLO—, and —CRK?CRL—; wherein ring A, ring B, and ring C are each independently a 5-membered carbocyclic ring, 5-membered heterocyclic ring, 6-membered carbocyclic ring or 6-membered heterocyclic ring; wherein LA is coordinated to a metal M forming a 5-membered chelate ring; wherein M is selected from the group consisting of Ir, Pt, Pd, Ru, Rh, Os, Re, Cu, Ag, and Au; wherein RA, RB, and RC each represent mono to the maximum allowable substitution, or no substitution; wherein each R, RK, RL, RM, RN, RA, RB, and RC is independently a hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, car